Court’s rejection of appeal against RPI-CPI decision is ‘another blow to public sector employees’, says FDA

20 March 2012
For immediate release

The Court of Appeal's decision to uphold the High Court ruling in favour of the Government's switch from RPI to CPI for uprating public sector pensions was described today by the FDA as "another blow to public sector employees". The FDA is the union representing the UK's senior public servants.

FDA general secretary Jonathan Baume said: "This is another blow to public sector employees, who are being asked to pay a disproportionate price for the failings of others. The uprating mechanism change from RPI to CPI means a real cut to our members' pensions. It comes on top of increased pension contributions and a two- or three-year pay freeze, followed by a 1% pay cap.

"We are, naturally, very disappointed with the decision of the Court of Appeal. The FDA gave a commitment following the decision in the High Court that we will continue to challenge where it makes sense to do so and where there is a reasonable prospect of success. This remains our position."

The FDA submitted an application for judicial review of the Government's decision in November 2011 - along with Prospect, the GMB, the NUT, the Police Federation and the Civil Service Pensioners' Alliance.

Notes for editors

1. The FDA is the trade union and professional body representing 18,000 of the UK's senior civil and public servants. Our members include policy advisors, senior managers, tax inspectors, economists, statisticians, accountants, special advisers, government lawyers, diplomats, crown prosecutors and NHS managers.

2. Members in HMRC are represented by the Association of Revenue and Customs (ARC), a section of the FDA.

3. The FDA (formerly the First Division Association) should be referred to simply as "The FDA" and can be described as "the senior public servants' union".

4. For further information contact:

  • Jonathan Baume, FDA General Secretary, tel: 020 7401 5555 or 07976 951191.
  • Oliver Rowe, FDA Communications Manager, tel: 020 7401 5588 or 07590 838696.